News | January 20, 2026
Alto Neuroscience bags new US patent for depression drug ALTO-207
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
Berendsen brings over 15 years of financial leadership experience spanning professional services and international trade
Over 8.8?million Indians aged 60 and above currently live with dementia,
The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
The collaboration centers on the "Life Doesn't Stop for a Hot Flash" campaign
The feature will be available across all Max Healthcare facilities, offering patients consistent and convenient access to services nationwide
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
Subscribe To Our Newsletter & Stay Updated
